A Phase I, Open-Label, Two-stage, Randomized, Crossover, Comparative Pharmacokinetic and Safety Study of Two Formulations of CO-1.01 for Injection in Patients With Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 21 Aug 2014
At a glance
- Drugs Gemcitabine elaidate (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- 18 Jun 2013 Results published in the Journal of Clinical Pharmacology.
- 13 Jun 2013 Primary endpoint 'Area-under-the-drug-concentration-time-curve' has not been met.
- 15 Feb 2013 Status changed from suspended to discontinued, based on a Clavis Pharma media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History